T1	Participants 68 104	patients with low ejection fractions
T2	Participants 349 398	6797 patients with ejection fractions < or = 0.35
T3	Participants 647 774	Patients with heart failure entered the treatment trial (n = 2569) and those without heart failure entered the prevention trial
T4	Participants 1757 1793	patients with low ejection fractions